NCT06723652

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 55 (actual)
• Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd · Industry
• Sex: All
• Age: 12 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study to assess the reduction of low-density lipoprotein cholesterol (LDL-C) by SHR-1918 in patients with homozygous familial hypercholesterolemia (HoFH).

Conditions

• Homozygous Familial Hypercholesterolemia

Interventions

Type	Name	Description
DRUG	SHR-1918	six administration
DRUG	SHR-1918 placebo	SHR-1918 placebo three administration+SHR-1918 three administration

Timeline

• Start date: 2025-02-13
• Primary completion: 2025-08-25
• Completion: 2025-11-18
• First posted: 2024-12-09
• Last updated: 2025-12-15

Locations

1 site across 1 country: China